Bristol-Myers Squibb Analyst Price Targets - Benzinga

Bristol-Myers Squibb Co

BMYNYSE

Trade with Public

Trade with Public

$62.40

-0.46-0.73%

마지막 업데이트: Sep 30, 7:52 PM

$62.45

-0.41-0.65%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 배당금 비교 옵션 주식 보고서

© 2026 Benzinga | All Rights Reserved

Bristol-Myers Squibb Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bristol-Myers Squibb (BMY).

Price Target Range — 12 Quarters

Analyst Consensus — 24 Analysts

10Buy

13Hold

1Sell

Consensus RatingNeutral# Analysts24Avg. Consensus PT$62Upside to Avg. PT-0.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 16, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$75→$82
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Hold	$60→$65
Aug 5, 2026	Argus Research	Jasper Hellweg	Upgrade	Hold→Buy	$75
Aug 3, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$66→$70
Jul 31, 2026	RBC Capital	Trung Huynh	PT Raise	Sector Perform	$60→$64
Jul 31, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$67→$73
Jul 31, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Neutral	$54→$59
Jul 31, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$60→$65
Jul 31, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$72→$75
Jul 31, 2026	Truist Securities	Robyn Karnauskas	Maintained	Buy	$65→$70
Jul 10, 2026	B of A Securities	Tim Anderson	PT Cut	Buy	$67→$66
Jul 6, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Neutral	$54
Apr 9, 2026	B of A Securities	Tim Anderson	PT Cut	Buy	$68→$67
Apr 8, 2026	Guggenheim	Seamus Fernandez	Maintained	Buy	$72
Apr 8, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Neutral	$45→$54
Mar 17, 2026	HSBC	Rajesh Kumar	PT Raise	Hold	$53→$60
Feb 25, 2026	RBC Capital	Trung Huynh	Initiate	Sector Perform	$60
Feb 23, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$66→$75
Feb 20, 2026	Barclays	Emily Field	Initiate	Overweight	$75
Feb 6, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$60→$64

More with Benzinga EdgeGet Access

Analyst Ratings News

This $3 Biotech Could Be Worth $11.45, Analyst Says

William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.

Vandana Singh

PRO
Piper Sandler Reiterates Overweight on Bristol-Myers Squibb, Raises Price Target to $82

Piper Sandler analyst David Amsellem reiterates Bristol-Myers Squibb (NYSE:BMY) with a Overweight and raises the price target from $75 to $82.

Benzinga Newsdesk

PRO
HSBC Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $65

HSBC analyst Rajesh Kumar maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and raises the price target from $60 to $65.

Benzinga Newsdesk

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector. Top analysts & recent news on PRGO, PFE, BMY.

Avi Kapoor

Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment

Bristol Myers Squibb secures FDA approval for Zenbexus (iberdomide), marking the first CELMoD therapy approval.

Vandana Singh

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

During market turbulence, investors turn to dividend-yielding stocks. Benzinga provides analyst ratings for high-yield stocks in health care.

Avi Kapoor